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ABSTRACT
Objectives We examined patient- reported outcomes 
(PROs) in The Study of Etanercept And Methotrexate in 
Patients with Psoriatic Arthritis (PsA); a 48- week, phase 
3, randomised controlled trial that compared outcomes 
with methotrexate (MTX) monotherapy, etanercept 
monotherapy, and MTX+ etanercept in patients with PsA.
Methods Efficacy endpoints included: mean changes 
from baseline and proportion of patients who reported 
improvements≥minimal clinically important difference 
(MCID) at week 24 in treatment groups for Health 
Assessment Questionnaire- Disability Index, Patient Global 
Assessment (PtGA), Patient Global Assessment of Joint 
Pain (PtGAJP) and Medical Outcomes Study Short Form-
36 Questionnaire (SF-36) Physical Component Summary 
(PCS), and Mental Component Summary, and eight domain 
scores. PROs were analysed as reported (observed), 
without multiplicity adjustment; therefore, p values are 
descriptive.
Results At week 24, patients receiving etanercept 
monotherapy or MTX+ etanercept combination reported 
greater improvements (p≤0.05) in PtGA, PtGAJP and 
SF-36 PCS scores compared with those receiving MTX 
monotherapy. Compared with MTX monotherapy, higher 
proportions of patients receiving etanercept monotherapy 
and combination therapy reported improvements≥MCID 
in PtGA (etanercept vs MTX, p=0.005) and PtGAJP (MTX 
+etanercept vs MTX, p=0.038). Across PROs, proportions 
of patients reporting scores≥age and gender- matched 
normative values at week 24 ranged from 20.8% to 51.0% 
with MTX monotherapy, 30.9% to 48.8% with etanercept 
monotherapy, and 30.6% to 52.3% with MTX+ etanercept 
combination.
Conclusions Patients receiving etanercept monotherapy 
or MTX+ etanercept reported greater improvements from 
baseline in several PROs compared with those receiving 
MTX monotherapy. PROs should be incorporated in 
discussions between patients and clinicians regarding 
their treatment choices as they can help determine 
which treatments are more beneficial in patients with 
PsA.
INTRODUCTION
Psoriatic arthritis (PsA) is a progressive, 
chronic inflammatory disease with both joint 
and skin- related manifestations. Patients with 
PsA can experience a multitude of symptoms 
including peripheral and axial joint inflam-
mation, enthesis inflammation (enthesitis; 
inflammation of the areas where tendons 
Key messages
What is already known about this subject?
 ► Patients with psoriatic arthritis (PsA) have lower 
health- related quality of life compared with the gen-
eral population, as measured by patient- reported 
outcomes (PROs). PROs can improve with common-
ly used treatments for PsA, such as methotrexate 
(MTX) and tumour necrosis factor inhibitors.
 ► However, few studies exist that have directly com-
pared the therapeutic effect of MTX with a tumour 
necrosis factor inhibitor on PROs in patients with 
PsA.
What does this study add?
 ► This study analyzes PRO data captured in a phase 
3, randomised controlled trial that directly compared 
the effect of MTX monotherapy versus etanercept 
(a tumour necrosis factor inhibitor) monotherapy 
or MTX plus etanercept combination therapy in pa-
tients with PsA who were treatment naïve.
 ► Etanercept monotherapy and combination therapy 
were more effective than MTX monotherapy for im-
provement in PROs (and, in many cases, clinically 
meaningful outcomes were reported) in patients 
with PsA.
How might this impact on clinical practice?
 ► Improvements in PROs with etanercept may inform 
decision- making between clinicians and patients 
with PsA.
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or ligaments attach to bones), finger or toe inflamma-
tion (dactylitis), nail disease and psoriasis.1 In patients 
with psoriasis, about 30% develop PsA with an annual 
incidence of 1%–3%.2–5 Effective disease management 
requires not only timely diagnosis and treatment but 
also recognition that PsA can adversely affect patient- 
reported outcomes (PROs). Previous research suggests 
that, in general, patients with PsA report worse PRO 
scores compared with either the general population or 
patients with psoriasis.6–9 PsA is associated with consider-
able disease burden including bodily pain and physical 
function below that of age- matched and gender- matched 
norms,10 fatigue, increased absenteeism from work, 
and decreased work productivity.11–14 When assessing 
the overall clinical value of PsA treatments, PRO meas-
ures should be included since health- related quality of 
life (HRQoL), physical function and global assessments 
are affected by treatment efficacy, safety, tolerability, 
dosing frequency and route of administration. Disease- 
modifying antirheumatic drugs (DMARDs) used to treat 
PsA such as methotrexate (MTX) and tumour necrosis 
factor inhibitors (TNFis) can improve PROs related to 
physical ability, joint pain and mental ability in patients 
with PsA.9 15 Although MTX, as a monotherapy or in a 
combination regimen, is widely used to treat PsA, the 
evidence supporting its use in this disease setting is 
limited. Further, few randomised controlled trials (RCTs) 
in PsA have examined PROs when directly comparing 
MTX with a TNFi or in combination with a TNFi. These 
include a study that compared MTX monotherapy versus 
placebo in patients with psoriasis16 and a study that 
compared MTX monotherapy versus golimumab and 
MTX combination therapy in patients with early PsA.17
The Study of Etanercept And Methotrexate in Combi-
nation or as Monotherapy in Subjects with Psoriatic 
Arthritis (SEAM- PsA)18 reported that both etanercept 
monotherapy and combination therapy were statistically 
significantly more effective than MTX monotherapy by 
the percentage of patients who were American College 
of Rheumatology 20% responders (ACR20, primary 
endpoint) and had Minimal Disease Activity (MDA) 
(key secondary endpoint) at week 24. Week-48 safety 
outcomes indicated that no deaths occurred in the study 
and that the incidences of adverse events and serious 
adverse events were similar across the three treatment 
groups.18 Published PRO results with the Health Assess-
ment Questionnaire- Disability Index (HAQ- DI) and the 
Medical Outcomes Study Short Form-36 Questionnaire 
(SF-36) showed similar improvements in HAQ- DI and 
Mental Component Summary (MCS) scores from base-
line to week 24 in all three treatment groups.18 However, 
the SF-36 Physical Component Summary (PCS) score 
showed greater mean changes from baseline at week 
24 in both etanercept groups compared with MTX 
monotherapy.
Here, we report additional PRO measures from the 
SEAM- PsA RCT examining the effect of MTX mono-
therapy, etanercept monotherapy, and MTX plus 
etanercept combination therapy on PROs that evalu-
ated HRQoL, physical function and global assessments 
of disease activity, including: HAQ- DI, Patient Global 
Assessment of disease activity (PtGA), Patient Global 
Assessment of Joint Pain (PtGAJP) and SF-36 summary 
and domain scores. By evaluating changes across the 3 
groups at week 24 and comparing scores to age- matched 
and gender- matched normative values (based on the 
general population without chronic disease), we aimed 
to examine improvements in PROs.
METHODS
Study design and patient population
SEAM- PsA was a 48- week, phase 3, multicentre, interna-
tional RCT conducted at 124 hospitals/centres/clinics 
in 17 countries ( ClinicalTrials. gov, NCT02376790). Key 
patient eligibility criteria included age ≥18 years old at 
screening, active PsA (based on Classification Criteria 
for Psoriatic Arthritis),19 naïve to etanercept and other 
biologic agents, no prior use of MTX for PsA (prior treat-
ment with MTX for psoriasis was allowed), ≥3 tender and 
≥3 swollen joints (68/66 tender/swollen joint count) at 
screening and baseline, and an active psoriatic skin lesion 
≥2 cm in diameter. Patients were randomised 1:1:1 via 
an interactive voice- response system to receive: (1) oral 
MTX (target 20 mg/week) plus subcutaneous placebo 
weekly, (2) etanercept 50 mg/week given subcutaneously 
plus oral placebo weekly, or (3) etanercept at 50 mg/
week given subcutaneously plus oral MTX weekly (target 
20 mg/week). Patients with an inadequate response at or 
after week 24 (<20% improvement in tender and swollen 
joint counts from baseline), received rescue therapy with 
etanercept (50 mg/week) plus MTX (target 20 mg/week) 
until week 48.
All PROs were evaluated at baseline and weeks 12, 24, 
36 and 48. At each visit, PROs were completed before 
administration of study medication and other study 
procedures.
The SEAM- PsA trial was conducted in accordance with 
the Declaration of Helsinki. Written informed consent 
was obtained from each patient, and each participating 
site obtained protocol approval by an institutional 
review board or independent ethics committee. Addi-
tional details about the design and eligibility criteria of 
SEAM- PsA have been previously published.18 20
Outcomes
The primary endpoint of the SEAM- PsA trial was the 
percentage of ACR20 responders at week 24, and the 
key secondary endpoint was the percentage of patients 
with MDA at week 24. These results have been previously 
published.18
Additional study endpoints included the change in 
PRO scores from baseline at week 24 in each treatment 
group by HAQ- DI, PtGA, PtGAJP, SF-36 PCS, MCS and 
eight individual domains: Physical Function, Role Phys-
ical, Bodily Pain, General Health, Vitality, Social Function, 
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Age in years, mean (SD) 48.7 (13.1) 48.5 (13.5) 48.1 (12.7)
Female sex, n (%) 160 (56.3) 133 (46.8) 139 (49.1)
White race, n (%) 255 (89.8) 252 (88.7) 265 (93.6)
Duration of PsA in years, mean (SD) 3.6 (6.8)* 3.1 (6.0)† 3.0 (6.0)*
Median (Q1, Q3) 0.9 (0.1, 3.3)* 0.6 (0.1, 3.0)† 0.5 (0.1, 3.0)*
Prior use of non- biological DMARD, n (%) 38 (13.4) 26 (9.2) 43 (15.2)
Body mass index (kg/m2), mean (SD) 30.6 (7.1) 30.4 (6.6)‡ 30.0 (6.7)
Swollen joint count (66 joints), mean (SD) 12.9 (9.9) 11.5 (9.6)‡ 11.2 (9.1)§
Tender joint count (68 joints), mean (SD) 20.9 (15.0) 18.8 (14.5)]‡ 20.0 (15.3)§
mTSS, mean (SE) 2.8 (0.1)¶ 3.0 (0.1)** 2.7 (0.1)††
PASDAS, mean (SE) 6.1 (0.1)§ 6.1 (0.1)‡‡ 6.0 (0.1)§§
DAPSA, mean (SE) 46.5 (1.4)‡ 43.4 (1.4)¶¶ 43.8 (1.4)¶¶
LDI
>0 at baseline, n (%) 98 (34.5) 96 (33.8) 90 (31.8)
Mean (SE) for patients with >0 at baseline 164.9 (26.9)*** 147.6 (20.8)††† 138.2 (23.9)‡‡‡
SPARCC Enthesitis Index
>0 at baseline, n (%) 191 (67.3) 189 (66.5) 196 (69.3)
Mean (SE) for patients with >0 at baseline 5.7 (0.3)§§§ 5.5 (0.3)¶¶¶ 5.9 (0.3)****
Psoriasis- affected BSA, mean % (SD) 12.7 (18.8) 10.8 (14.7) 10.7 (15.6)
sPGA, mean (SD) 2.6 (1.1) 2.6 (1.0) 2.5 (1.0)‡
HAQ- DI, mean (SE) 1.3 (0.04)‡ 1.2 (0.04) 1.2 (0.04)§
Patient Global Assessment (0–100), mean (SE) 60.7 (1.3)‡ 62.9 (1.3) 61.0 (1.2)§
Patient Global Assessment of Joint Pain (0–100), mean (SE) 56.1 (1.3)‡ 56.5 (1.3) 55.7 (1.3)§
SF-36 PCS, mean (SE) 35.6 (0.5)§ 37.8 (0.5) 37.4 (0.6)§
SF-36 MCS, mean (SE) 45.2 (0.7)§ 45.1 (0.7) 46.3 (0.7)§
SF-36 domains, mean (SE)
  Physical function 42.1 (1.5)§ 48.5 (1.5) 49.0 (1.5)§
  Role physical 44.6 (1.5)§ 48.5 (1.5) 50.2 (1.5)§
  Bodily pain 36.3 (1.1)§ 39.8 (1.1) 39.3 (1.1)§
  General health 46.1 (1.1)§ 48.1 (1.3) 47.1 (1.2)§
  Vitality 40.2 (1.2)§ 43.1 (1.3) 42.0 (1.2)§
  Social function 58.3 (1.6)§ 62.7 (1.6) 63.3 (1.6)§
  Role emotional 65.8 (1.7)§ 65.4 (1.7) 70.0 (1.6)§
  Mental health 60.3 (1.3)§ 60.8 (1.3) 62.5 (1.2)§
*Number of patients analysed for mean values=231.
†Number of patients analysed for mean values=222.
‡Number of patients analysed for mean values=283.
§Number of patients analysed for mean values=282.
¶Number of patients analysed for mean values=269.
**Number of patients analysed for mean values=273.
††Number of patients analysed for mean values=274.
‡‡Number of patients analysed for mean values=279.
§§Number of patients analysed for mean values=280.
¶¶Number of patients analysed for mean values=281.
***Number of patients analysed for mean values=98.
†††Number of patients analysed for mean values=96.
‡‡‡Number of patients analysed for mean values=90.
§§§Number of patients analysed for mean values=191.
¶¶¶Number of patients analysed for mean values=189.
****Number of patients analysed for mean values=196.
BSA, body surface area; DAPSA, Disease Activity Index for Psoriatic Arthritis; DMARD, disease- modifying antirheumatic drug; HAQ- DI, Health Assessment 
Questionnaire- Disability Index; LDI, Leeds Dactylitis Index; MCS, Mental Component Summary; mTSS, van der Heijde modified Total Sharp Score; PASDAS, 
Psoriatic Arthritis Disease Activity Score; PCS, Physical Component Summary; PsA, psoriatic arthritis; Q1, first quartile; Q3, third quartile; SE, standard error; 
SF-36, Medical Outcomes Study Short Form-36 Questionnaire; SPARCC, Spondyloarthritis Research Consortium of Canada; sPGA, static Physician Global 
Assessment.
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Role Emotional, and Mental Health. Exploratory analyses 
examined the proportion of patients in each treatment 
group who reported improvements from baseline at week 
24≥minimal clinically important differences (MCID; 
which is the degree of change that is perceptible and clin-
ically meaningful to patients21) in HAQ- DI, PtGA, PtGAJP 
and SF-36 PCS, MCS and the domains.22–25 We also 
examined the proportion of patients in each treatment 
group who reported scores at week 24≥age- matched and 
gender- matched normative values in HAQ- DI and SF-36 
PCS, MCS and domain scores.26 There are no normative 
values defined for PtGA and PtGAJP.
Statistical analyses
SEAM- PsA was not powered to detect differences between 
PROs. As such, p values for efficacy endpoints other 
than the primary and key secondary endpoints were 
not adjusted for multiplicity and should be considered 
descriptive. All treatment comparisons were performed 
using the Cochran- Mantel- Haenszel test with prior use of 
non- biological DMARDS (non- bDMARDS) and a base-
line body mass index (BMI) status (≤30 kg/m2 or >30 kg/
m2) as stratification factors. An analysis of covariance 
(ANCOVA) model that adjusted for baseline BMI status 
and prior non- bDMARD use compared the treatment 
differences between the MTX monotherapy group versus 
the two etanercept- containing groups for changes in 
PRO scores at week 24 from baseline. Statistical analyses 
were performed using SAS V.9.4 (SAS Institute).
RESULTS
Patient characteristics
A total of 851 patients completed the study. Baseline 
demographic and disease characteristics were well 
balanced across the three treatment groups (table 1). 
Most patients were Caucasian (90.7%), and mean (SD) 
age was 48.4 (13.1) years. Most patients were early in the 
course of their disease, with the mean (SD) duration of 
PsA of 3.2 (6.3) years (median 0.6 years). Prior MTX 
for the treatment of psoriasis was received by 4.9% of 
patients. From weeks 4 to 24, patients in the MTX groups 
continued a mean MTX dose that was >18.8 mg (median 
20 mg).
Change in PRO scores
An examination of changes in PRO scores from base-
line to week 24 indicated that improvements generally 
occurred across all three treatment groups. For most 
SF-36 domains, changes from baseline at week 24 were 
numerically higher in the etanercept groups compared 
with MTX monotherapy (table 2).
Treatment differences between MTX monotherapy 
versus the two etanercept groups by changes in PRO 
scores at week 24 after adjusting for baseline BMI status 
Table 2 Change in patient- reported outcome scores from baseline at week 24
Patient- reported outcome: least square 







HAQ- DI* –0.39 –0.41 –0.44
PtGA* –22.70 –31.64† –29.04‡
PtGAJP* –18.95 –24.12‡ –24.90‡
SF-36 PCS§ 5.68 7.38‡ 7.62‡
SF-36 MCS§ 3.48 2.99 3.46
SF-36 domain scores§
  Physical function 14.47 17.42 17.54
  Role physical 13.81 16.28 17.66
  Bodily pain 16.03 20.47‡ 21.66¶
  General health 7.77 11.93¶ 10.9
  Vitality 10.46 10.99 13.94‡
  Social function 14.58 11.37 13.22
  Role emotional 8.58 9.76 8.08
  Mental health 6.92 7.5 8.91
*For HAQ- DI, PtGA and PtGAJP, a lower score indicates a more positive health state, so greater negative changes from baseline indicate 
improvement.
†P value for comparison with methotrexate monotherapy was ≤0.001.
‡P value for comparison with methotrexate monotherapy was ≤0.05.
§For SF-36, a higher score indicates a more positive health state, so greater positive changes from baseline indicate improvement.
¶P value for comparison with methotrexate monotherapy was ≤0.01.
HAQ- DI, Health Assessment Questionnaire- Disability Index; MCS, Mental Component Summary; PCS, Physical Component Summary; 
PtGA, Patient Global Assessment; PtGAJP, Patient Global Assessment of Joint Pain; SF-36, Medical Outcomes Study Short Form-36 
Questionnaire.
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and prior non- bDMARD use are shown in table 2. 
Patients receiving etanercept monotherapy reported 
greater improvements from baseline in PtGA (p<0.001), 
PtGAJP (p=0.032), SF-36 PCS (p=0.033) and the domains 
of Bodily Pain (p=0.034) and General Health (p=0.01) 
compared with MTX monotherapy. Patients receiving 
combination therapy reported greater improvements 
from baseline in PtGA (p=0.012), PtGAJP (p=0.014), 
SF-36 PCS (p=0.015), Bodily Pain (p=0.007), and Vitality 
(p=0.05) domains compared with MTX monotherapy.
We generated a spydergram (figure 1) to illustrate how 
mean baseline and week 24 SF-36 domain scores across 
treatment groups compared against USA age- matched 
and gender- matched normative scores matched to the 
protocol population.27 Published normative values are: 
HAQ- DI: ≤0.25, SF-36 PCS and MCS: ≥50, and domain 
scores listed in the figure legend, with missing values not 
imputed. Figure 1 illustrates how the largest differences 
between MTX monotherapy and etanercept treatment 
groups were reported in Bodily Pain, General Health, 
and Vitality Domains.
Threshold analyses
Patients reporting improvements in PRO scores at week 24 ≥ 
MCID
We examined the percentage of patients in each treat-
ment group who reported changes in PRO scores at week 
24≥MCID in HAQ- DI, PtGA, PtGAJP and SF-36 PCS, 
MCS and domains. The etanercept monotherapy and 
combination therapy groups generally included a higher 
percentage of patients reporting clinically meaningful 
changes in PRO scores at week 24 (figure 2) compared 
with MTX monotherapy. The highest percentages of clin-
ically meaningful improvements were reported in PtGA 
(66.7% with MTX monotherapy vs 78.3% with etanercept 
monotherapy, and 75.1% with combination therapy). 
Analyses comparing across treatment groups generally 
showed similar proportions of patients reporting chang-
es≥MCID at week 24. Exceptions were higher percentages 
in both etanercept groups in PtGA (66.7% with MTX 
monotherapy vs 78.3% with etanercept monotherapy; 
p=0.005) and PtGAJP (65.1% with MTX monotherapy vs 
73.9% with combination therapy; p=0.038; figure 2).
Patients reporting PRO scores ≥ age-matched and gender-
matched normative values at week 24
Across PROs, the percentages of patients reporting 
scores at week 24≥normative values ranged from 20.8% 
(General Health domain) to 51.0% (SF-36 MCS) with 
MTX monotherapy, 30.9% (Role Physical domain) to 
48.8% (SF-36 MCS) with etanercept monotherapy, and 
30.6% (General Health domain) to 52.3% (SF-36 MCS) 
with combination therapy (figure 3). Higher percentages 
of patients in both etanercept groups reported scores at 
week 24≥normative values (p≤0.05) in HAQ- DI, SF-36 
PCS, and Role Physical, Bodily Pain, and General Health 
domains. Numerically, more patients receiving combina-
tion therapy reported scores at week 24≥normative values 
in Vitality and Mental Health domains compared with 
MTX monotherapy (p≤0.05; figure 3).
DISCUSSION
Our analyses of the PRO data collected from the 
SEAM- PsA RCT indicate that patients receiving MTX 
monotherapy, etanercept monotherapy and MTX plus 
etanercept all reported improvements in PRO scores 
at week 24 compared with baseline. Both the etaner-
cept monotherapy and MTX plus etanercept groups 
reported greater improvements from baseline compared 
with MTX in PtGA, PtGAJP, SF-36 PCS and Bodily Pain 
domain. Additionally, the etanercept monotherapy 
group reported greater improvement in General Health 
and the combination therapy group greater improve-
ment in Vitality compared with MTX monotherapy. 
Improvements in PROs reported with etanercept mono-
therapy and MTX plus etanercept were numerically 
similar, although this was not statistically evaluated as the 
trial was not powered for statistical comparison between 
these two groups.
Figure 1 Spydergram of domain scores from baseline 
to week 24 versus age- matched and gender- matched 
normative scores. The spydergram was generated using 
domain raw scores (range: 0–100); age- gender norms in 
the USA were matched to the study population. The age- 
matched and gender- matched normative values for the 
SF-36 domains were: 82.01 for PF, 82.55 for RP, 72.86 for 
BP, 70.31 for GH, 58.89 for VT, 85.11 for SF, 88.12 for RE 
and 75.94 for MH. Missing values were not imputed. A 
higher SF-36 score indicates a more positive health state, 
so greater positive changes from baseline. P values in red 
indicate p≤0.05; p values in blue indicate p≤0.01. A, age; BL, 
baseline; BP, Bodily Pain; ETN, etanercept; G, gender; GH, 
General Health; MH, Mental Health; MTX, methotrexate; PF, 
Physical Function; RE, Role Emotional; RP, Role Physical; SF, 
Social Function; VT, Vitality; Wk, week.
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Reported results indicated that treating patients with 
PsA with etanercept either monotherapy or in combina-
tion with MTX results in greater, more clinically mean-
ingful improvements in PROs compared with MTX 
monotherapy. Results from the primary and secondary 
endpoints of SEAM- PsA, for which the RCT analyses were 
powered, indicate that etanercept monotherapy and 
combination therapy were statistically significantly more 
effective than MTX monotherapy by ACR20 responses 
and MDA at week 24.18 PRO results from these analyses 
most closely aligned with ACR responses and MDA at 
week 24 are those examining changes from baseline at 
Figure 2 Percentages of patients reporting PRO improvements≥MCID week 24. *P values are descriptive and are for 
comparison with methotrexate monotherapy. Only p values ≤0.05 are shown. MCID values were change from baseline ≤ 
–0.35 for HAQ- DI, ≤ –10.0 for PtGA, ≤ –10.0 for PtGAJP, ≥2.5 for SF-36 PCS, ≥2.5 for SF-36 MCS, and ≥5.0 for each SF-36 
domain. BP, Bodily Pain; GH, General Health; HAQ- DI, Health Assessment Questionnaire- Disability Index; MCID, minimal 
clinically important difference; MCS, Mental Component Summary; MH, Mental Health; PCS, Physical Component Summary; 
PF, Physical Function; PRO, patient- reported outcome; PtGA, Patient Global Assessment; PtGAJP, Patient Global Assessment 
of Joint Pain; RE, Role Emotional; RP, Role Physical; SF, Social Function; SF-36, Medical Outcomes Study Short Form-36 
Questionnaire; VT, vitality.
Figure 3 Percentages of patients reporting PRO scores ≥normative values at week 24. *P values are descriptive and are for 
comparison with methotrexate monotherapy at week 24. Only P values ≤0.05 are shown. Normative values were ≤0.25 for 
HAQ- DI; ≥50 for SF-36 PCS, and ≥50 for SF-36 MCS. Age/gender normalised values for the SF-36 domains were 82.01 for 
PF, 82.55 for RP, 72.86 for BP, 70.31 for GH, 58.89 for VT, 85.11 for SF, 88.12 for RE, and 75.94 for MH. BP, Bodily Pain, GH, 
General Health; HAQ- DI, Health Assessment Questionnaire- Disability Index; MCS, Mental Component Summary; MH, Mental 
Health; PCS, Physical Component Summary; PF, Physical Function; PRO, patient- reported outcome; RE, Role Emotional; RP, 
Role Physical; SF, Social Function; SF-36, Medical Outcomes Study Short Form-36 Questionnaire; VT, Vitality.
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week 24 in PtGA, PtGAJP, SF-36 PCS, and General Health 
domain. These PROs may be most sensitive for capturing 
how patients with PsA experience their disease.
The internal validity of our study’s results is strength-
ened due to SEAM- PsA being an active- comparator RCT 
that directly compared PROs in patients treated with 
MTX, etanercept and combination therapy. In addition, 
the active comparator included patients receiving MTX 
at currently recommended doses (~20 mg/week).28
Results from our study are different from those 
observed in a phase 3 trial of golimumab in combination 
with MTX versus MTX monotherapy,17 in which golim-
umab did not show significant improvements in physical 
PCS at week 22 (SF-36 PCS score of 50.1 vs 50.7; p=0.543). 
In our study, etanercept monotherapy or in combina-
tion with MTX showed significant improvements in PCS 
scores at week 24 vs MTX monotherapy (least squares 
mean change from baseline in SF-36 PCS score of 7.38 
and 7.62, respectively, vs 5.68; p≤0.05) for both compar-
isons. However, similar to observations in our study, the 
golimumab trial did not find any significant improve-
ments in MCS scores.17
This study has a few limitations. There was no placebo 
group in the trial. This is important because including a 
placebo arm could help contextualise the results of this 
trial with prior RCTs in PsA. It is well known that active 
comparator trials, without placebo, result in higher 
responses as all patients have higher ‘expectation bias’, 
knowing that they are all receiving active treatment.29 30 
However, there are ethical issues regarding prolonged 
placebo exposure in patients with active, especially early 
disease. Another limitation is that the SEAM- PsA trial 
was not powered to detect differences between etaner-
cept groups and thus they could not be compared. The 
most important limitation was the generalisability of our 
results, as the treatment- naïve population enrolled in this 
RCT may not reflect the experiences of typical patients 
with severe or moderate PsA. However, our results are 
likely most relevant to patients with relatively early, active 
PsA disease.
Future research in PsA should include active compara-
tors and PROs in their design. In addition, direct compar-
isons between different treatments could help determine 
which treatments are more effective in patients with PsA. 
Considering results from this RCT, PROs should be incor-
porated in discussions between patients and clinicians 
regarding their choice of treatment, to incorporate the 
patient’s perspective. Improvements in PROs reported 
with etanercept may inform decision- making between 
clinicians and patients with PsA.
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